Pancreatic cancer is one of the most lethal cancers worldwide. No effective screening methods exist, and available treatment modalities do not effectively treat the disease. Inflammatory conditions such as pancreatitis represent a well-known risk factor for pancreatic cancer development. Yet only in the past 2 decades has pancreatic cancer been recognized as an inflammation-driven cancer, and the precise mechanisms underlying the pathogenic role of inflammation are beginning to be explored in detail. A substantial amount of preclinical and clinical evidence suggests that bacteria are likely to influence this process by activating immune receptors and perpetuating cancer-associated inflammation. The recent explosion of investigations of the human microbiome have highlighted how perturbations of commensal bacterial populations can promote inflammation and promote disease processes, including carcinogenesis. The elucidation of the interplay between inflammation and microbiome in the context of pancreatic carcinogenesis will provide novel targets for intervention to prevent and treat pancreatic cancer more efficiently. Further studies toward this direction are urgently needed.
T he immune system is one of the main defense mechanisms of the human organism against carcinogenesis. Immune cells continuously patrol almost every site of the human body and destroy cells that display features of incipient transformation. Conversely, cancer cells in advanced tumors find ways to cloak themselves from immune surveillance, either by down-regulating their tumor-specific antigens or by suppressing the antitumor immune cells, leading to immune evasion and escape. 1, 2 Furthermore, tumor cells may manipulate the immune system in ways that support tumor growth and sustain a microenvironment favorable for cancer progression and hostile to different means of anticancer treatment modalities, be it chemotherapy, radiation, or targeted therapy. 2 This type of tumor-associated inflammation has recently been appreciated as a novel "enabling characteristic" in the latest Hallmarks of Cancer review because it can facilitate the acquisition of multiple already defined hallmarks of cancer, thus pointing out its critical role in carcinogenesis. 3 Pancreatic ductal adenocarcinoma (PDAC) represents the quintessential example of an inflammation-driven cancer. This is supported by epidemiological data and evidence from preclinical models and clinical studies. In this review, we discuss the recent advances pertaining to the link between inflammation, microbiome, and pancreatic cancer and present our perspective on this topic.
INFLAMMATION AND PANCREATIC CANCER
In the case of pancreatic cancer, inflammation is relevant both as a risk factor for and as a consequence of the cancer. Patients with hereditary autoimmune pancreatitis have an estimated lifetime risk for PDAC development of 40%, 4 whereas patients with chronic pancreatitis carry a 13-fold higher risk of PDAC development. 5 The duration of pancreatitis seems to correlate positively with the possibility of Kras mutations, 6 which suggests a possible mutagenic role for repetitive bouts of inflammation. Interestingly, however, most PDAC cases develop in the absence of clinically evident overt pancreatitis. 7 Therefore, we can conclude that either subclinical low-grade inflammation is sufficient to promote carcinogenesis or inflammation is a consequence of the earliest events in the stepwise process of pancreatic carcinogenesis. This low-grade inflammation, which is a result of cellular stress and malfunction, has been termed parainflammation and is hypothesized to either contribute to cellular adaptation to the noxious environment or promote senescence to prevent malignant transformation. 8 A considerable amount of evidence has accumulated in the past decade from work done on genetically engineered mouse models that recapitulate the sequence of events occurring in human PDAC. 9 Kras is mutated in more than 90% of human PDAC cases, and constitutive activation within the pancreas results in PDAC development in mice in a fashion very similar to its human counterpart. 10, 11 There seems to be a cooperative relationship between Kras activation and inflammation. 12, 13 Specifically, p48 +/Cre ;LsL-Kras G12D ("KC") mice, which have mutant Kras expressed prenatally in all exocrine pancreatic lineages, exhibit pancreatitis as one of the earliest morphologic changes in their pancreas. In addition, treatment of these mice with only a few doses of cerulein, a cholecystokinin analog that hyperstimulates the pancreas and induces pancreatitis if injected repeatedly, dramatically accelerates the progression to advanced pancreatic intraepithelial neoplasia (PanIN) and invasive cancer within a few weeks (compared to months in untreated mice). 14 A seminal discovery was made by Guerra et al who used a Cre/Tetracycline-off system to activate the Kras mutation in acinar cells of adult mice. Surprisingly, these mice only developed pancreatic cancer when chronic pancreatitis was induced with cerulein, suggesting that Kras mutation alone, in the absence of pancreatitis, is not sufficient to induce pancreatic cancer in adulthood. 15 The same group has shown that chronic pancreatitis enables Kras-driven carcinogenesis by thwarting oncogeneinduced senescence (OIS), a homeostatic mechanism that diverts stressed cells prone to malignant transformation toward cell cycle arrest and quiescence. 16 Concurrent treatment of the mice with a cyclooxygenase (COX)1/2 inhibitor not only prevented the progression of early PanIN to advanced PanIN and invasive cancer but also decreased the number of early PanIN lesions, pointing to additional mechanisms through which inflammation promotes pancreatic carcinogenesis. 16 Logsdon and colleagues have studied the role of inflammation and its influence on Kras-driven carcinogenesis from a different perspective. 17, 18 They showed that even when Kras is mutated and constitutively active, it cannot reach the expected theoretical levels of activity and remains at levels close to the basal state. 17 However, inflammatory insults such as cerulein and lipopolysaccharide (LPS) can hyperstimulate Kras, bringing its activity above the hypothetical threshold necessary for the initiation of the sequence of carcinogenesis. 17, 18 Furthermore, constitutive activation of both Kras and either IKK2 (an activator of the nuclear factor kappa B [NF-κB] pathway) or COX2 (a downstream effector of the NF-κB pathway) in acinar cells dramatically accelerates carcinogenesis. 18 On the other hand, ablation of IKK2 mitigated the cerulein-induced inflammation and fibrosis, decreased the levels of active Kras, and protected against PanIN formation. 18 Similar results were observed with inhibition of COX2. 18 Additional evidence was provided by a different study, which showed that mutant Kras induces the transcription of IL-1α through AP-1. IL-1α in turn activates the NF-κB pathway leading to production of more IL-1α as well as activation of the signaling adaptor p62, which prolongs the activity of this pathway. 19 A very intriguing finding was that in the context of chronic pancreatitis and tissue injury, Kras mutation can give rise to PDAC originating from insulinpositive endocrine cells. 20 The significance of this lies in the fact that chronic inflammation can induce de-differentiation of committed epithelial cells and thence promote carcinogenesis. In summary, inflammation synergizes with Kras through the establishment of a positive feedback loop that is dependent on NF-κB and COX2 and leads to sustained Kras activity; on the other hand, Kras activity promotes an IL-1α-and p62-mediated feed-forward loop that sustains NF-κB pathway activity.
Several other mechanisms contributing to inflammationdriven carcinogenesis in PDAC have been identified to date. A notable example is STAT3, which seems to be a central player in pancreatic carcinogenesis. STAT3 is activated in mice challenged with cerulein. In wild type (WT) mice, the activation status reverts to baseline after a few days consistent with recovery from acute pancreatitis. In contrast, in KC mice, STAT3 remains persistently activated. 21 This is a consequence of communication between the epithelial cells and the surrounding stromal cells. Specifically, the Kras-mutant epithelial cells recruit myeloid cells that secrete IL-6 and activate the STAT3 pathway in the epithelial cells via IL-6 trans-signaling, thus completing a positive feedback loop. 22 Persistent STAT3 activation drives pancreatic cancer progression through up-regulation of antiapoptotic and proproliferative proteins such as Bcl-X L , Mcl-1, survivin, c-Myc, and cyclin D1. [21] [22] [23] In incipient carcinogenesis, this may be critical for the evasion of OIS, whereas later on, it may be more important for proliferation under the adverse conditions of the hypoxic tumor microenvironment. Moreover, STAT3 activation in epithelial cells promotes the secretion of proinflammatory mediators, which further recruit leukocytes; at the same time, epithelial STAT3 signaling induces the expression of matrix metallopeptidase 7 (MMP7), which supports tumor growth and metastasis. 21 Genetic ablation of IL-6 or STAT3, neutralization of IL-6 trans-signaling, and deletion of STAT3 exclusively in the epithelial cells dampens tumor-associated inflammation and protects from spontaneous and cerulein-induced PanIN formation and PDAC development. 21, 22 The pancreatic tumor microenvironment is rife with factors that can attract inflammatory cells and entrain them to support the process of carcinogenesis and shield the cancer cells from the antitumorigenic arm of the immune system. Kras-mutant epithelial cells secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) to recruit myeloid cells that suppress CD8 + cytotoxic T cells. 24, 25 The secretion of granulocyte-macrophage colony-stimulating factor begins early on, and its neutralization depletes myeloid-derived suppressor cells and enables efficient tumor killing by CD8 + T cells. 24, 25 In a similar fashion, pancreatic cancer cells produce the chemokine CCL2 that mobilizes inflammatory monocytes from the bone marrow and recruits them to the pancreas as well as to premetastatic niches such as the liver to promote tumor growth and metastasis, respectively. 26 Cancer cells also secrete CCL5 and other ligands that recruit regulatory T cells in a CCR5-dependent manner and thus contribute to an immunosuppressive tumor microenvironment. 27 Several studies have shown that cancer cells can also influence the immune response indirectly by manipulating other stromal cells. Notably, cancer-associated fibroblasts (CAFs), which in pancreatic cancer may originate from pancreatic stellate cells (PSCs), are induced to express an NF-κB-dependent proinflammatory gene signature that enhances tumor growth, vascularization and macrophage recruitment. 28 Second, inflammatory mediators such as IL-1β and tumor necrosis factor released by the cancer cells instruct CAFs to release thymic stromal lymphopoietin, which in turn signals to myeloid dendritic cells to skew CD4 + T cells toward helper T cell (T H )2 polarization. 29 T H 2-deviated CD4 + T cells have a procarcinogenic role in the pancreas through the perpetuation of pancreatic fibroinflammation and the recruitment of M2 macrophages. 29, 30 Third, activated PSCs up-regulate adhesion molecules and secrete chemokines, the most prominent being CXCL12, which sequester CD8 + T cells around them and prevent them from attacking the cancer cells. 31 Another study validated these results and further showed that fibroblast activation protein-expressing CAFs secreting CXCL12 are the limiting factor for the efficacy of T-cell checkpoint inhibitors. 32 Inhibition of CXCL12 reverses the immunosuppressive effects of PSC/CAFs and synergizes with anti-PD-L1 immunotherapy leading to tumor elimination. 31, 32 Given the fact that inflammation is such an important contributor and is present very early in the stepwise process of pancreatic carcinogenesis, it is reasonable to assume that it would be an attractive target for chemoprevention. Indeed, multiple approaches have been adopted using either natural compounds with diverse effects or synthetic compounds that have specific targets. 33 For example, inhibition of cyclooxygenases has been investigated in multiple studies using both nonsteroidal antiinflammatory drugs (aspirin, nimesulide, etodolac, sulindac, etc) and COX2-specific inhibitors (e.g., celecoxib). 33, 34 Several of those have been associated with decreased risk of pancreatic cancer. 33, 34 Curcumin, an agent with pleiotropic effects on the tumor stroma and the associated inflammation, also seems to have a protective effect in pancreatic carcinogenesis. 33 Prospective studies in larger cohorts are required to address the efficacy of such compounds in preventing pancreatic cancer.
MICROBIOME AND PANCREATIC CANCER
Infectious agents are estimated to be responsible for 10% to 20% of all cancers globally, 35 yet none has been established as causative for pancreatic cancer so far. However, in the last few years, several studies have presented tangential evidence that suggests a possible role of microbes in the pathogenesis of pancreatic cancer (Tables 1 and 2 ). Previous studies have attempted to associate pathogens such as Helicobacter pylori with pancreatic cancer using serologic and culture-based methods ( Table 2) . However, the fact that an overwhelming percentage of the commensal microflora are noncultivable has precluded objective investigation of their influence in such diseases as pancreatitis. 37 New techniques such as next generation sequencing and metagenomics now enable a representative evaluation of the microbiotic communities in health and disease, and their dynamic interactions with their human host. 44 More importantly, the human microbiome has only recently been appreciated as an indispensable factor for the normal development of the immune system and as a key modulator of disease when the homeostatic relations between host and microorganisms are deranged. [52] [53] [54] In the latter state, called dysbiosis, certain members of the microbial community may decrease in numbers and their place may be taken by other, less prevalent bacteria that can become pathogenic if they reach high concentrations, hence termed pathobionts. The role of such global shifts in the microbiome composition rather than causative role of specific pathogens has not been evaluated in the context of pancreatic carcinogenesis. Environmental insults can alter the composition of the intestinal microflora and also increase the intestinal permeability, allowing pathobionts to gain access to the bloodstream and reach distant organs. For example, alcohol consumption, the most common cause for chronic pancreatitis, has been linked to dysfunction of the intestinal barrier function and overgrowth of gram-negative bacteria in the intestine, leading to elevated systemic levels of LPS. [55] [56] [57] In addition, bacteria administered orally to healthy WT mice can reach the pancreas and persist there for several hours (C.P.Z. and G.M., unpublished data). We believe that reflux of intestinal contents through the main pancreatic duct may be a second route through which bacteria can access the pancreas.
Another situation that may permit bacterial translocation is poor oral hygiene and associated diseases. It is well established that individuals with periodontitis and tooth loss, conditions caused by dysbiosis of oral bacteria, are at increased risk for pancreatic cancer. 46, [58] [59] [60] A recent epidemiologic study presented more convincing evidence for this by revealing associations between specific profiles of oral bacteria and increased risk of pancreatitis and pancreatic cancer ( Table 2) . 45 Interestingly, this latter study investigated the use of the discovered bacterial profiles as biomarkers for pancreatitis and pancreatic cancer and has thus exemplified how perturbations in the microbiome of the gastrointestinal tract may be exploited as biomarkers for noninvasive screening of pancreatic disease. 45 The most plausible mechanism for the procarcinogenic effect of microbes seems to involve chronic low-grade activation of the immune system and perpetuation of tumor-associated inflammation, rather than direct mutagenic effects (Fig. 1) . Toll-like receptors (TLRs) represent the best-described family of pattern recognition receptors (PRRs). They are present on most types of immune cells, and they bind a variety of microbe-associated molecular patterns (such as LPS) and byproducts of dying cells and sterile inflammation denoted damage-associated molecular patterns. 61 Upon ligand binding, they recruit either the myeloid differentiation primary response gene 88 or the TIR-domaincontaining adapter-inducing interferon-β adaptor molecules (depending on the specific TLR) to transduce activation signals to the NF-κB and MAPK pathways. We found that TLR4 and TLR7 are up-regulated within the tumor microenvironment of pancreatic cancer. 42, 43 Furthermore, we and others have shown that TLR activation can fuel pancreatitis and can synergize with Kras to dramatically accelerate pancreatic carcinogenesis in mice. 18, 36, 37, 42, 43 These procarcinogenic effects of TLRs can be prevented through inhibition of either NF-κB or MAPK pathway. 42 Furthermore, mice deficient in several TLRs are protected from acute pancreatitis ( Table 1) . Direct inhibition of TLR4 and TLR7 protects KC mice from pancreatic carcinogenesis. 42, 43 Other PRRs and associated signaling molecules have been implicated in the pathogenesis of inflammation-driven cancer. Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are cytoplasmic PRRs. When engaged by their ligands, they can activate the NF-κB pathway, but they also associate with other molecules to form large oligomeric complexes called inflammasomes. 62 Caspase-1 is a key component of activated inflammasomes and is responsible for the proteolytic cleavage and maturation of the proinflammatory cytokines IL-1β and IL-18. 62 NLRs and their downstream effectors are necessary for keeping the intestinal microbiota under control. For example, mice deficient in several NLRs, caspase-1, or IL-18 exhibit alterations in the gut microbiome and dysbiosis and are highly susceptible to colorectal carcinogenesis. 63 Consistent with their proinflammatory role, the in flammasomes have been found to contribute to the pathogenesis of pancreatitis. 38, 39 Specifically, administration of a NOD1 agonist synergized with cerulein in the induction of acute pancreatitis. 39 This was a result of NOD1 activation in acinar cells, which promoted acinar NF-κB and STAT3 signaling, and CCL2-mediated recruitment of CCR2 + proinflammatory cells. 39 Furthermore, genetic ablation of NOD1, Nlrp3, caspase-1, or ASC (another component of the inflammasome) protects from cerulein-induced acute pancreatitis. 38, 39 The implication of bacterial dysbiosis in pancreatic carcinogenesis has very interesting ramifications. Although genetically identical, the current genetically engineered mouse models of pancreatic cancer exhibit variability in the rate and extent of tumor progression, such that even age-matched littermate mice can have significantly different tumors. 10 This variability may well be explained by variations in the commensal microbiota of these mice. In the same manner, variations in the gastrointestinal tract microbiome may have prognostic significance in patients with newly diagnosed pancreatic cancer, with certain bacterial profiles correlating with more aggressive disease. Conversely, alterations of the intestinal microbiome that occur before the appearance of clinically detectable disease may be exploited toward the development of new preclinical screening tests for the early diagnosis of pancreatic cancer. These hypotheses deserve further investigation.
Recent studies on the influence of the microbiome in carcinogenesis have highlighted crucial roles in other gastrointestinal malignancies such as colon and liver cancer, both of which have an important inflammatory component (studies summarized in Schwabe and Jobin 54 ). An invaluable tool for these studies has been the ability to generate and maintain germ-free mice. In most models, germ-free mice have been found to be less prone to carcinogenesis, likely because of less tumor-associated inflammation. 54 These results have also been reproduced in using antibiotictreated mice that decrease the microbial load of the gut. 54 Similar experiments need to be conducted using mouse models of pancreatic cancer. Notably, bowel sterilization with broad-spectrum antibiotics has been shown to have a protective effect in acute pancreatitis. 39 On the other hand, administration of antibioticresistant Escherichia coli to bowel-sterilized mice undergoing acute pancreatitis results in more severe disease. 39 Since the intestinal microbiome is modifiable, it may represent a potential new target for therapeutic intervention. This may be achieved by targeted antibiotic therapy to eradicate the microbial species that are associated with an increased pancreatic cancer risk as well as other methods such as probiotics to (re)introduce the species that are associated with a decreased cancer risk. Moreover, modification of the intestinal microbiome An unexpected role of dysbiosis has been revealed very recently through 2 seminal studies that investigated its impact on the efficacy of anticancer chemotherapy and immunotherapy. 64, 65 The rationale behind the studies was that patients treated with chemotherapy often develop mucositis, which impairs the intestinal barrier function, and neutropenia, which requires the administration of broad-spectrum antibiotics that can potentially cause perturbations in the gut microbiome. The first study showed that cyclophosphamide alters the composition of the gut microbiome in mice and promotes the translocation of certain gram-positive bacteria to secondary lymphoid organs. 64 The bacteria in turn prime the immune system to generate T H 1-and T H 17-deviated T cells that are necessary for the immune-mediated tumoricidal effects of chemotherapy. 64 The second study had similar findings with oxaliplatin and further expanded to show that the absence of gut microbiota compromises the efficacy of CpG-and anti-IL-10-based immunotherapy owing to ineffective priming of tumor-infiltrating myeloid cells and consequently lack of reactive oxygen species-dependent apoptosis and tumor necrosis factor-dependent necrosis. 65 These findings highlight how iatrogenic factors can lead to disequilibrium in the commensal flora and how this can affect not only disease progression but also response to treatment.
CONCLUSION
It is well established that inflammation is a critical factor in pancreatic carcinogenesis, beginning at a very early stage. The mechanisms involved are just beginning to be uncovered in detail. Furthermore, the microbiome seems to be intricately connected to cancer-associated inflammation. The elucidation of the interplay between these 2 factors will allow us to identify FIGURE 1. Summary of the interplay between tumor-associated inflammation and microbiome as well as their key roles in pancreatic carcinogenesis. Pancreatic cancer progresses through a series of defined stages that involve acinar-to-ductal metaplasia (ADM) in response to repetitive injury, development of pre-neoplastic lesions, and eventually invasive cancer. (1) Pancreatitis can be caused by genetic and environmental factors (e.g. alcohol), and can promote pancreatic carcinogenesis by inducing ADM while inhibiting OIS. (2) Noxious stimuli to the pancreas result in a low-grade maladaptive inflammatory response termed "parainflammation" that can synergize with mutant Kras in tumor development and evasion of OIS (3), and recruit immune cells that promote cancer-associated inflammation (4) . Environmental factors, such as antibiotics and alcohol consumption, as well as pancreatitis can cause derangement of the gut microbiome and compromise the intestinal barrier function to promote translocation of bacteria to the pancreas (5) . Translocated dysbiotic bacteria (pathobionts) can stimulate PRRs and inflammasomes and perpetuate tumor-associated inflammation. Treatment modalities such as chemotherapy and radiotherapy can also influence the microbiome; alterations in the microbiome (dysbiosis) can have detrimental effects on the efficacy of chemotherapy and immunotherapy (6) . CAF, cancer-associated fibroblasts; DC, dendritic cells; GIT, gastrointestinal tract; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; MDSC, myeloid-derived suppressor cells; OIS, oncogene-induced senescence; PanIN, pancreatic intraepithelial neoplasia; PRRs, pattern-recognition receptors; PSC, pancreatic stellate cells; TAM, tumor-associated macrophages.
novel targets for intervention to prevent and treat pancreatic cancer more efficiently. Finally, the microbiome holds promise as a biomarker for early detection of pancreatic cancer. Further studies are urgently needed to address the exciting hypothesis of a procarcinogenic role of perturbed gut microbiome in pancreatic cancer.
